These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 20458537)

  • 1. Indinavir-induced nephrolithiasis three and one-half years after cessation of indinavir therapy.
    Huynh J; Hever A; Tom T; Sim JJ
    Int Urol Nephrol; 2011 Jun; 43(2):571-3. PubMed ID: 20458537
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk factors for urological symptoms in a cohort of users of the HIV protease inhibitor indinavir sulfate: the ATHENA cohort.
    Dieleman JP; Sturkenboom MC; Jambroes M; Gyssens IC; Weverling GJ; ten Veen JH; Schrey G; Reiss P; Stricker BH;
    Arch Intern Med; 2002 Jul; 162(13):1493-501. PubMed ID: 12090886
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Indinavir trough concentration as a determinant of early nephrolithiasis in HIV-1-infected adults.
    Collin F; Chêne G; Retout S; Peytavin G; Salmon D; Bouvet E; Raffi F; Garraffo R; Mentré F; Duval X;
    Ther Drug Monit; 2007 Apr; 29(2):164-70. PubMed ID: 17417069
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nephrolithiasis on indinavir.
    Prescrire Int; 1999 Feb; 8(39):22. PubMed ID: 10557573
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acute tubulointerstitial nephritis attributable to indinavir therapy.
    Jaradat M; Phillips C; Yum MN; Cushing H; Moe S
    Am J Kidney Dis; 2000 Apr; 35(4):E16. PubMed ID: 10739809
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Indinavir urinary stones as origin of upper urinary tract obstruction.
    John H; Müller NJ; Opravil M; Hauri D
    Urol Int; 1997; 59(4):257-9. PubMed ID: 9444746
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Protease inhibitor-induced urolithiasis.
    Gentle DL; Stoller ML; Jarrett TW; Ward JF; Geib KS; Wood AF
    Urology; 1997 Oct; 50(4):508-11. PubMed ID: 9338723
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased incidence of indinavir nephrolithiasis in patients with hepatitis B or C virus infection.
    Malavaud B; Dinh B; Bonnet E; Izopet J; Payen JL; Marchou B
    Antivir Ther; 2000 Mar; 5(1):3-5. PubMed ID: 10846585
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increased prevalence and analysis of risk factors for indinavir nephrolithiasis.
    Saltel E; Angel JB; Futter NG; Walsh WG; O'Rourke K; Mahoney JE
    J Urol; 2000 Dec; 164(6):1895-7. PubMed ID: 11061951
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Nephrolithiasis in a HIV infected patient treated with indinavir].
    Brzósko S; Hryszko T; Panasiuk B; Prokopowicz D; Myśliwiec M
    Przegl Lek; 2001; 58(6):528-9. PubMed ID: 11816748
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Papillary necrosis associated with the HIV protease inhibitor indinavir.
    Dieleman JP; van der Feltz M; Bangma CH; Stricker BH; van der Ende ME
    Infection; 2001 Aug; 29(4):232-3. PubMed ID: 11545487
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Influence of environmental temperature on incidence of indinavir-related nephrolithiasis.
    Martínez E; Leguizamón M; Mallolas J; Miró JM; Gatell JM
    Clin Infect Dis; 1999 Aug; 29(2):422-5. PubMed ID: 10476752
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A pilot, double-blind, placebo-controlled trial of indinavir in patients with ALS.
    Scelsa SN; MacGowan DJ; Mitsumoto H; Imperato T; LeValley AJ; Liu MH; DelBene M; Kim MY
    Neurology; 2005 Apr; 64(7):1298-300. PubMed ID: 15824372
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics of indinavir and ritonavir administered at 667 and 100 milligrams, respectively, every 12 hours compared with indinavir administered at 800 milligrams every 8 hours in human immunodeficiency virus-infected patients.
    Rhame FS; Rawlins SL; Petruschke RA; Erb TA; Winchell GA; Wilson HM; Edelman JM; Abramson MA
    Antimicrob Agents Chemother; 2004 Nov; 48(11):4200-8. PubMed ID: 15504842
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Indinavir nephropathy in an AIDS patient with renal insufficiency and pyuria.
    Perazella MA; Kashgarian M; Cooney E
    Clin Nephrol; 1998 Sep; 50(3):194-6. PubMed ID: 9776425
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acute renal failure due to indinavir crystalluria and nephrolithiasis: report of two cases.
    Berns JS; Cohen RM; Silverman M; Turner J
    Am J Kidney Dis; 1997 Oct; 30(4):558-60. PubMed ID: 9328372
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anuria and acute renal failure resulting from indinavir sulfate induced nephrolithiasis.
    Witte M; Tobon A; Gruenenfelder J; Goldfarb R; Coburn M
    J Urol; 1998 Feb; 159(2):498-9. PubMed ID: 9649271
    [No Abstract]   [Full Text] [Related]  

  • 18. Urolithiasis and the protease inhibitor indinavir.
    Hermieu J; Prévot M; Ravery V; Sauty L; Moulinier F; Delmas V; Bouvet E; Boccon-Gibod L
    Eur Urol; 1999; 35(3):239-41. PubMed ID: 10072627
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Atazanavir-induced nephrolithiasis].
    Valencia ME; Moreno V
    Enferm Infecc Microbiol Clin; 2009 Feb; 27(2):134-5. PubMed ID: 19246127
    [No Abstract]   [Full Text] [Related]  

  • 20. Toxicity. Milk thistle and indinavir.
    TreatmentUpdate; 2002; 14(7):4-5. PubMed ID: 12400499
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.